Literature DB >> 21108333

Duration of viral shedding in patients admitted to hospital with pandemic influenza A/H1N1 2009 infection.

Shin Na1, Yong Pil Chong, Mi-Na Kim, Won Young Kim, Won Kim, Sang-Bum Hong, Chae-Man Lim, Younsuck Koh, Ji-Won Kwon, Soo-Jong Hong, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Jun Hee Woo, Sung-Han Kim.   

Abstract

Little is known about the kinetics of viral shedding of pandemic influenza A/H1N1 2009 virus. Influenza RNA, as a surrogate for viral clearance, was therefore measured on days 1, 5, 7, and 10 or more in patients admitted to hospital with pandemic influenza A/H1N1 2009 infection. A total of 72 patients who were admitted to hospital with confirmed pandemic influenza A/H1N1 2009 at a tertiary care hospital, Seoul, South Korea, between 1 September and 11 November 2009 were evaluated. The median duration of viral shedding, as assessed by RT-PCR, was 9 days, as determined by the Kaplan-Meier method. Patients who were positive by RT-PCR at their last assay, but who were discharged before the next RT-PCR test due to symptom improvement, were censored from the analysis. If such patients were included, with the assumption that they had negative viral status at discharge, the median duration of viral shedding was 5 days (interquartile range, 2-8 days). These calculations thus suggest that the true median duration of viral shedding is between 5 and 9 days. Univariate analysis showed that delayed administration of antiviral therapy and comorbidity were associated with slower viral clearance. Multivariate analysis showed that oseltamivir started after the first day of symptoms (OR 2.7, 95% CI 1.2-5.7) was associated independently with slower viral clearance. These findings indicate that, in about 50% of patients admitted to hospital with pandemic influenza A/H1N1 2009, virus can be positive as tested by RT-PCR on the eighth day after developing symptoms of influenza. The present findings also indicate that starting antiviral therapy within 24 hr of the onset of symptoms is associated with more rapid viral clearance.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21108333     DOI: 10.1002/jmv.21935

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  12 in total

1.  Effects of influenza antivirals on individual and population immunity over many epidemic waves.

Authors:  K M Pepin; S Riley; B T Grenfell
Journal:  Epidemiol Infect       Date:  2012-03-30       Impact factor: 2.451

2.  Predictors of pneumococcal co-infection for patients with pandemic (H1N1) 2009.

Authors:  Mar Masiá; Sergio Padilla; Pedro Antequera; José Manuel Ramos; Montserrat Ruiz; Félix Gutiérrez
Journal:  Emerg Infect Dis       Date:  2011-08       Impact factor: 6.883

3.  Three cases of acute myositis in adults following influenza-like illness during the H1N1 pandemic.

Authors:  Summer Bell Gibson; Jennifer Juhl Majersik; A Gordon Smith; Mark B Bromberg
Journal:  J Neurosci Rural Pract       Date:  2013-01

4.  Lessons from a one-year hospital-based surveillance of acute respiratory infections in Berlin- comparing case definitions to monitor influenza.

Authors:  Matthias Nachtnebel; Benedikt Greutelaers; Gerhard Falkenhorst; Pernille Jorgensen; Manuel Dehnert; Brunhilde Schweiger; Christian Träder; Silke Buda; Tim Eckmanns; Ole Wichmann; Wiebke Hellenbrand
Journal:  BMC Public Health       Date:  2012-03-27       Impact factor: 3.295

5.  Pandemic Risk Assessment Model (PRAM): a mathematical modeling approach to pandemic influenza planning.

Authors:  D C Dover; E M Kirwin; N Hernandez-Ceron; K A Nelson
Journal:  Epidemiol Infect       Date:  2016-08-22       Impact factor: 4.434

6.  Viral load dynamics in adult patients with A(H1N1)pdm09 influenza.

Authors:  J Y Noh; J Y Song; S Y Hwang; W S Choi; J Y Heo; H J Cheong; W J Kim
Journal:  Epidemiol Infect       Date:  2013-07-18       Impact factor: 4.434

7.  Course of pandemic influenza A(H1N1) 2009 virus infection in Dutch patients.

Authors:  Ingrid H M Friesema; Adam Meijer; Arianne B van Gageldonk-Lafeber; Mariken van der Lubben; Janko van Beek; Gé A Donker; Jan M Prins; Menno D de Jong; Simone Boskamp; Leslie D Isken; Marion P G Koopmans; Marianne A B van der Sande
Journal:  Influenza Other Respir Viruses       Date:  2012-02-28       Impact factor: 4.380

8.  Duration of Influenza Virus Shedding Among HIV-Infected Adults in the cART Era, 2010-2011.

Authors:  Pragna Patel; Timothy Bush; E Milu Kojic; Edgar T Overton; Keith Henry; Nur Önen; Frank Rhame; Lois Conley; John T Brooks; Alicia Fry
Journal:  AIDS Res Hum Retroviruses       Date:  2016-06-13       Impact factor: 2.205

9.  Factors promoting the prolonged shedding of the pandemic (H1N1) 2009 influenza virus in patients treated with oseltamivir for 5 days.

Authors:  Seung M Ryoo; Won Y Kim; Chang H Sohn; Dong W Seo; Bum J Oh; Jae H Lee; Yoon S Lee; Kyoung S Lim
Journal:  Influenza Other Respir Viruses       Date:  2012-12-26       Impact factor: 4.380

10.  Comparison of patients hospitalized with COVID-19, H7N9 and H1N1.

Authors:  Li-Si Deng; Jing Yuan; Li Ding; Yuan-Li Chen; Chao-Hui Zhao; Gong-Qi Chen; Xing-Hua Li; Xiao-He Li; Wen-Tao Luo; Jian-Feng Lan; Guo-Yu Tan; Sheng-Hong Tang; Jin-Yu Xia; Xi Liu
Journal:  Infect Dis Poverty       Date:  2020-12-02       Impact factor: 4.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.